Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers.
A third-party randomized trial from King’s College London is being cited as the reason Johnson & Johnson’s Impella usage has ...
A work is seen blow a Xiaomi logo at the east China headquarters of electronics and car-maker Xiaomi, in Nanjing, in China's eastern Jiangsu province on May 26, 2026. CN-STR/Getty images Xiaomi ...
Jul 16, 2026-- Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a nex ...
Storage resilience built to meet the performance demands of agentic AI SUNNYVALE, CA / ACCESS Newswire / July 15, 2026 ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV treatment and prevention will be presented at the 26th ...
S&P 500 and Nasdaq rise after June CPI data comes in soft, while the Dow opens lower. Here's what the split market open means ...
A liquid embolic procedure reduces the need for repeated surgical drainage in elderly patients managing chronic subdural ...
Inside the cell nucleus, genes must be turned on and off with precision to regulate biological processes. The first models of ...
Integrating case counts with genomic sequences quantifies real-time transmission advantages of viral variants.
The tech giant says a breakthrough in data center networking has dramatically accelerated the flow of information through its massive cloud infrastructure. The new technology hinges on a “quasi-random ...
Whole-blood transfusion has recently gained favor in the management of severe hemorrhage; however, data from large clinical trials evaluating its clinical effectiveness and safety are lacking. We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results